Overview of Ralgro

Ralgro: A Non-Steroidal Anabolic Agent

Ralgro is a specialized veterinary pharmaceutical product defined by its active ingredient, Zeranol, and its classification as an anabolic agent and non-steroidal estrogen agonist. It is used as an agent for growth promotion in livestock, specifically beef cattle. Its distinction lies in its non-steroidal structure, which allows it to mimic the anabolic and growth-regulating effects of natural estrogens without introducing traditional steroidal hormones. The product is used in the market for promoting growth performance and increasing weaning weights.

Composition, Origin, and Pharmaceutical Form

The compound Zeranol is chemically identified as alpha-zearalanol. It is a synthetic derivative structurally derived from the natural mycotoxin zearalenone, a fungal metabolite. Chemically, Zeranol belongs to the group of resorcylic acid lactones (RALs); its template comes from a naturally occurring biological source but is modified for enhanced efficacy. The dosage form for Ralgro is the subcutaneous implant, a solid preparation consisting of compressed pellets. This solid form is administered beneath the skin, allowing for a prolonged and consistent release of Zeranol over an extended duration.

General Purpose of the Zeranol Implant

The general purpose of administering the Zeranol implant is to promote enhanced biological efficiency in target animals. By stimulating anabolic processes, the product acts to increase nitrogen retention and protein synthesis. The practical result of this action is an increased rate of weight gain and an improvement in feed efficiency. The design is directed toward maximizing the utilization of consumed nutrients for efficient growth.

Regulatory References

What side effects are possible with Ralgro?

Possible side effects and safety information

The safety profile of Ralgro, which is based on the non-steroidal estrogen agonist Zeranol, is officially documented by regulatory authorities, such as the FDA, with adverse reactions categorized by the physiological systems they affect.

Regulatory documents do not classify the frequency of these effects using standard tiers (e.g., common, rare).

Officially Documented Adverse Reactions

The primary adverse effects are grouped into Reproductive System and Musculoskeletal System disorders. Documented changes include specific physical alterations such as elevated tailheads and pinched loins. Reactions related to the reproductive system can manifest as udder development and the exhibition of signs of estrus (heat), primarily noted in heifers.

Serious Adverse Reactions and Population Constraints

The official labeling identifies vaginal and/or rectal prolapse as serious adverse reactions that may occur. This highlights a critical safety tier within the product’s profile.

Safety is further defined by strict limitations regarding the target animal population. The product is strictly contraindicated for use in all breeding stock, including breeding bulls and replacement beef heifers after weaning, due to the risk of reproductive safety consequences. Furthermore, adverse reproductive effects are most frequently observed in heifers.

These official classifications define the risk profile by associating the estrogenic action of Zeranol with a range of specific, observable physical and reproductive changes in cattle, establishing clear regulatory boundaries for its approved use.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information for Zeranol

The following information is derived from government-approved regulatory documents for the implant containing the active ingredient, Zeranol.

Documented Manifestations of Over-Exposure

Over-Implantation in Target Animals (Cattle): Over-exposure is documented to result in pronounced manifestations related to the drug's estrogenic activity. These signs, listed in the official labeling, include:

Edema of the vulva and edema of the udder.
Teat elongation.
Signs of estrus when implanted in non-estrus animals.
Structural complications such as vaginal prolapse and rectal prolapse.
In young males, over-exposure may cause delayed testicular development.

Mandatory Emergency Actions

The product is strictly labeled Not for use in humans. The official user safety warnings mandate immediate action in the event of accidental human exposure:

When Immediate Medical Help is Required: Accidental human ingestion of the implant requires immediate consultation with a physician or emergency services.
Dermal/Ocular Contact: If irritation or symptoms occur or persist following skin or eye contact with the product, a physician must be consulted.

Officially Described Supportive Measures: Official safety information directs that vomiting must not be induced unless explicitly instructed by a qualified medical professional or Poison Control Center. Management of over-exposure is limited to symptomatic and supportive treatment, as no specific antidote is known or documented in the regulatory prescribing information.

Population Note: Regulatory documents emphasize the warning to Keep out of reach of children regarding the implant, due to the risk of accidental ingestion.

Therapeutic Uses of Ralgro

Ralgro (Zeranol) is a specialized veterinary product applied to support key performance metrics in beef cattle, focused on supporting optimal growth and efficiency throughout their productive life. It is utilized for increased rate of weight gain and improved feed efficiency across different cattle groups.

The product is commonly used in conditions presenting with periods related to suboptimal daily gain and the functional challenge of inefficient feed conversion. The primary focus is supporting the increased rate of weight gain and improved feed efficiency in growing beef steers and heifers, as well as in beef calves two months of age or older.

Enhanced Growth Rate and Physical Development

The primary use is to manage the condition of suboptimal daily gain in growing cattle, which refers to an accumulation of body mass slower than the animal’s potential. It is applied to healthy, growing stock—including suckling calves, stockers, and feedlot animals—to support an improved rate of weight gain. This application may assist with achieving heavier weaning weights in calves and supports the cattle in reaching market weight targets more efficiently.

“The application supports the animal’s ability to convert feed into lean muscle mass efficiently.”

Improved Nutrient Utilization and Feed Efficiency

Ralgro is relevant in contexts where cattle require a disproportionately high amount of feed to produce a measurable unit of body mass. The agent helps support a greater proportion of consumed nutrients being directed toward building lean muscle tissue. This contributes to improved feed efficiency, which, in turn, contributes to economic efficiency by contributing to reduced feed consumption relative to the weight gained.

Support for Suboptimal Growth Ralgro is used to help manage the functional challenge of inefficient feed conversion and the condition of suboptimal daily gain in beef cattle across growing and finishing phases.

Regulatory References

NIH DailyMed official labeling

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Ralgro (zeranol) is a specialized product designated for veterinary use only and is strictly prohibited for use in humans. Official regulatory labeling defines eligibility based on the animal's species, age, and production status.

Category	Eligibility Status	Specific Population Restrictions
Species	Allowed	Growing beef steers and heifers (stocker, feeder, dry lot, or fed for slaughter).
	Contraindicated	Humans (Not for use in humans).
Age Group	Allowed	Beef calves 2 months of age or older.
	Prohibited	Beef calves less than 2 months of age; effectiveness and safety are not established.
Reproductive Status	Contraindicated	Bulls intended for reproduction, dairy cows, and replacement dairy heifers.
	Restricted Use	Replacement beef heifers must not be used after weaning.
Conditional Use	Not Approved	Reimplantation (repeated implantation within a single production phase) is not approved, as safety and effectiveness have not been evaluated.
	Contraindicated	Veal calves; the product is not for use in calves to be processed for veal.

These official eligibility constraints ensure the product is used only in the specified cattle populations for which safety and effectiveness have been established by regulatory authorities.

What should I know about interactions with other medicines?

Ralgro Interactions with other medicines and products

Official regulatory information for the Zeranol implant is focused on constraints related to co-administration with other implants and specific procedural prohibitions. The official labeling does not include data on classic drug-drug interaction mechanisms, such as those mediated by Cytochrome P450 enzymes (CYP) or drug transporters, as is common for human pharmaceuticals.

Administration Prohibitions

The most significant interaction-related restriction is a formal prohibition on concurrent or sequential use with other implants. The product is not approved for repeated implantation with Ralgro or any other cattle ear implant within a single production phase. This constraint defines a mandatory temporal boundary for the administration of similar medicinal products (implants).

Classification	Restriction Summary
Prohibited Combination	Not approved for repeated or sequential implantation with any other cattle ear implant in a single phase.
Timing-based Rule	Implies mandatory separation from other implants during the same production period.

Procedural and Food Chain Restrictions

A critical restriction addresses the interaction with the food chain. The official regulatory documents formally mandate that the implanted site must not be salvaged for use as human or animal food. This constraint functions as a mandatory food safety measure enforced to prevent the potential entry of drug residue from the implant site into the food supply.

Mechanism of Action

How Ralgro Works: Endocrine and Anabolic Signaling

Estrogen Receptor-Mediated Action

Ralgro’s active component, zeranol, functions as a synthetic non-steroidal estrogen analog. It primarily acts as an agonist by engaging and binding to estrogen receptors located within target cells. This receptor binding initiates or suppresses downstream signaling sequences that regulate gene expression. This activity effectively modulates processes driven by distinct hormonal patterns, which influence subsequent protein and lipid metabolism.

Somatotropic Axis Modulation

Zeranol's mechanism extends to modifying the somatotropic axis, a key regulatory system involving the release of growth hormone (Somatotropin or ST) and the activity of Insulin-like Growth Factor-1 (IGF-1). The drug's action is associated with altered circulating ST levels and a modulation of IGF-1 production and receptor characteristics. This causes a cascade that alters the partitioning of nutrients within relevant metabolic pathways.

Cellular Protein Metabolism

A direct mechanistic consequence is the modification of overall protein turnover and nitrogen utilization at the cellular level. By affecting the somatotropic pathway, Ralgro engages mechanisms that shift the balance to favor protein synthesis while potentially reducing protein degradation within muscle tissue. This physiological adjustment alters the state of nitrogen balance, resulting in a net shift toward protein deposition.

Dosage and Administration Information

Administration Protocol for the Zeranol Implant

Ralgro is administered as a subcutaneous implant containing the active ingredient, Zeranol. The designated route involves placement beneath the skin. The drug is supplied as compressed pellets, and the administration is a fixed-dose, procedural event not tied to feeding time.

The standard labeled dose for general beef cattle is a single implant containing 36 mg of Zeranol, delivered as three 12 mg pellets. A higher-strength 72 mg implant, delivered as six pellets, is also used for steers fed in confinement.

The administration schedule follows a single-event pattern per production phase, providing a sustained release effect over an extended duration, and re-implantation within the same phase is not recommended. Procedurally, the implant is placed only in the ear (the middle one-third of the posterior aspect) using a dedicated pellet injector, and the site requires aseptic technique before implantation.

Use is restricted to specific populations: it is for beef calves 2 months of age or older, and is not for use in breeding bulls, dairy calves, veal calves, or dairy cows. These instructions define the protocol for use, ensuring standardized delivery of the Zeranol dose.

Recent Clinical Evidence

Research evidence / Overview of Studies for Ralgro

The clinical evaluation of Zeranol (the active ingredient in Ralgro) was evaluated in numerous controlled research settings in research exploring performance outcomes relevant to its authorized use in beef cattle. The research base, summarized by regulatory bodies, primarily consists of randomized controlled trials (RCTs) and pooled analyses that research examined performance outcomes in livestock.

Evidence for Use in Supporting Suboptimal Daily Weight Gain

The core evidence supporting this indication was studied in research examining performance outcomes related to daily mass accumulation. The research describes numerous controlled field investigations, which research examined performance metrics in implanted animals compared to non-implanted control groups. Researchers primarily monitored the Average Daily Gain (ADG) and the Total Final Liveweight recorded at the end of the experimental phase.

Findings describe patterns observed in the studies where the animals that received the implant recorded distinct measurements of ADG when compared to the control group. This research contributes to the broader evidence landscape that includes studies of growing beef cattle, such as suckling calves and feedlot steers and heifers.

Evidence for Use in Supporting Inefficient Feed Conversion

Research addressing the study of feed conversion performance was evaluated in controlled feeding trials. The primary performance metric research monitored was Feed Conversion Ratio (FCR), which is the amount of feed consumed relative to the live weight gained.

The data show patterns related to FCR measurements, where the implanted groups recorded distinct ratios when compared to the non-implanted control animals. Studies report how the observed populations used dry matter feed relative to the weight they accumulated during the study period. The research describes measurements of feed utilization efficiency.

Study Scope and Follow-up Duration

The research trials were observed in study durations designed to cover typical production cycles. The key clinical evaluation studies often focused on research exploring short-term performance changes, tracking performance for periods ranging from approximately 90 to 120 days. The trials included populations of healthy, growing beef cattle across various groups, reflecting the primary study populations.

What Remains Unclear or Subject to Variability

While a consistent pattern of measured outcomes was observed in the research, long-term effects are not fully established. The primary trials provide comprehensive performance metrics only over the specific, defined study intervals. Furthermore, comparative evidence is limited regarding extensive head-to-head studies against all other available growth technologies. Differences recorded in the measured outcomes (e.g., ADG and FCR) may be linked to the animal's life stage, the specific feed provided, and other factors.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Ralgro (FAQ)

Q: Is Ralgro safe to use for older adults?

According to official product information, Ralgro is designated strictly for veterinary use only in specific populations of beef cattle. Regulatory labeling includes a formal User Safety Warning: Not for use in humans.

Q: How does Ralgro affect the liver?

Official research studies examining the product's use in cattle included monitoring certain blood components related to liver function, such as glutamic oxaloacetic transaminase (GOT) and lactate dehydrogenase (LDH). Additionally, official residue and metabolism studies indicate that the liver contained the highest concentration of the drug residue in cattle at 15 days post-implantation.

Q: Can Ralgro cause long-term side effects that I should know about?

Official regulatory documents indicate that long-term effects are not fully established, as the core clinical trials tracked outcomes only over defined short-term study intervals, typically around 90 to 120 days. This finding is consistent with the product not being approved for repeated implantation (re-implantation) within a single production phase.

Q: What kind of studies were done before Ralgro was approved?

The research base summarized by regulatory bodies primarily consists of randomized controlled trials (RCTs) and controlled field investigations. These studies examined the product's performance outcomes in livestock across various production metrics before approval.

Q: Is Ralgro the same kind of medication as other similar drugs?

Official product information classifies Ralgro's active ingredient, zeranol, as a non-steroidal estrogen agonist and an anabolic agent. This classification defines its fundamental pharmacological type.

Q: How quickly can someone generally expect Ralgro to start working?

Supporting data indicates that measurable levels of the active ingredient are typically reached within the first day of administration. The subcutaneous implant is designed to provide a sustained release effect over an extended period.

Q: What happens if I forget to take Ralgro one day?

This product is an implant administered as a single subcutaneous pellet, not a daily oral medication. The administration schedule is a fixed, single-event procedure designed for sustained release over an entire production phase. It does not require daily dosing.

Q: Can Ralgro affect the results of common lab tests?

Research studies on implanted animals included monitoring various blood components. These studies noted changes in various blood components, such as increased concentrations of glutamic oxaloacetic transaminase (GOT), lactate dehydrogenase (LDH), and creatinine in implanted male animals.

Q: Does Ralgro have any known withdrawal symptoms if stopped suddenly?

Regulatory documents confirm that when the product is used strictly according to its official labeling, no withdrawal period is required. The drug is designed to be administered as a single implant per production phase.

Q: Are there any dietary restrictions or foods to avoid while using Ralgro?

Official regulatory documents contain mandatory restrictions against using the implant site for human or animal food and prohibit co-administration with other implants. However, the regulatory labeling does not describe any specific dietary restrictions for the target animal during the use of Ralgro.

Q: Can Ralgro cause unintended weight changes?

The official approved indication for Ralgro is specifically to achieve an increased rate of weight gain and improved feed efficiency in target animals. The product is designed to promote anabolic (building up) processes that result in this outcome.

Q: What happens to the body if Ralgro is used for a very long time?

Regulatory documents state that long-term effects are not fully established. The primary clinical trials that established the product’s profile only tracked performance over defined intervals, such as 90 to 120 days. The drug is intended to be used within defined production phases.

Q: Why is Ralgro only available by prescription?

According to official labeling by regulatory bodies, Ralgro is classified as an Over-the-Counter (OTC) Animal Drug for its approved use in livestock. The product is thus available for use in the approved animal populations without requiring a prescription.

Q: Does Ralgro come in different strengths or forms?

Ralgro is administered only as a subcutaneous implant (pellet form). It is available in a standard labeled dose of 36 mg of Zeranol (three 12 mg pellets) and a higher-strength 72 mg implant (six pellets).

Q: Are there different types of interactions to be aware of besides drug-to-drug?

Yes, regulatory documents highlight two primary restriction types. These include a constraint on co-administration with other implants (re-implantation is not approved within a single production phase) and a mandatory restriction on salvaging the implanted site for human or animal food.

How should Ralgro be stored and disposed of?

How to Store and Dispose of Ralgro?

Regulatory labeling outlines specific storage conditions for Ralgro (zeranol implant) to maintain its stability.

Storage Requirements

Requirement Category	Official Storage Statement
Temperature	Store between 2 and 25 C (36 and 77 F), or 15 to 30 C regionally.
Protection	Must be protected from light and kept in a dry, cool, well-ventilated area.
Packaging	Store in the closed original container.
Child Safety	Keep out of the sight and reach of children.

Disposal Instructions

Official disposal rules specifically instruct: Do not attempt to salvage the implant site for human or animal food. Any unused or expired product must be disposed of in accordance with applicable local pharmaceutical waste regulations.

Ralgro